Related Experiment Video
Updated: Jun 8, 2026
08:53
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Targeting Fas in osteoresorptive disorders
Natasa Kovacic1, Danka Grcevic, Vedran Katavic
1University of Zagreb School of Medicine, Department of Anatomy, Zagreb, HR-10000, Croatia. natasa@mef.hr
Expert Opinion on Therapeutic Targets
|September 22, 2010
Summary
The Fas-Fas ligand system mediates bone loss in estrogen deficiency and inflammation. Tissue-specific therapies targeting Fas signaling in bone cells are needed for osteoresorptive disorders.
Area of Science:
- Bone Biology
- Cell Signaling
- Apoptosis
Background:
- The Fas receptor initiates external apoptotic pathways in various cells.
- Fas receptor is implicated in mediating osteoresorptive effects linked to estrogen deficiency and inflammation.
Purpose of the Study:
- To review the expression and function of the Fas-Fas ligand system in bone cells.
- To explore its role in osteoresorption pathogenesis and potential therapeutic modulation.
Main Methods:
- Review of research over the past two decades.
- Analysis of in vitro, animal, and human studies.
- Examination of Fas-Fas ligand system structure, function, and signaling pathways.
Main Results:
- The Fas-Fas ligand system's non-apoptotic signaling pathways influence osteoblast differentiation.
- In vitro and in vivo data confirm its involvement in osteoresorptive disorders.
- Potential therapeutic strategies for modulating Fas function are discussed.
Conclusions:
- Tissue-specific therapeutic approaches are crucial for modifying the Fas-Fas ligand system in osteoresorptive disorders due to side effects of systemic targeting.
- Targeting Fas signaling molecules in conjunction with osteoblast/osteoclast differentiation pathways shows promise.
- Further research is needed to precisely define these therapeutic targets.
